Alvotech Reports Results of AVT02 (biosimilar- adalimumab) in AVT02-GL-302 Study to Treat Chronic Diseases
Shots:
- The AVT02-GL-302 study evaluates AVT02 in 568 patients at ~30 centers in the EU. Patients were randomized into either of the two arms of the switching module: The first group continues with Humira & the 2nd group is given AVT02 and Humira for an additional 16wks.
- The switching study (AVT02-GL-302) aims to support the approval of AVT02 in the US as an interchangeable biosimilar product with the high concentration (100mg/mL) dosage forms of Humira
- The results showed the bioequivalence of repeated switches b/w Humira & Alvotech’s AVT02- no significant differences were identified in clinical efficacy- safety- or immunogenicity b/w the switching cohort and Humira
| Ref: Alvotech| Image: Businesswire
Click here to read the full press release
Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com
